Treatment of hepatorenal syndrome: Vasoconstriction or vasodilation?
DOI:10.3969/j.issn.1001-5256.2020.11.005
- VernacularTitle:肝肾综合征的治疗：缩血管还是扩血管治疗？
- Author:
Xiaoyun LI
1
;
Jing HUA
Author Information
1. Department of Gastroenterology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai 200001, China
- Publication Type:Research Article
- Keywords:
hepatorenal syndrome;
vasoconstrictor agents;
therapeutics
- From:
Journal of Clinical Hepatology
2020;36(11):2419-2422
- CountryChina
- Language:Chinese
-
Abstract:
Hepatorenal syndrome (HRS) is a serious complication that occurs in patients with decompensated cirrhosis or acute/chronic liver failure. The main pathological features of HRS include marked peripheral vasodilation and strong renal vasoconstriction, with rapid progression, unsatisfactory treatment response, and poor prognosis. Vasoconstrictors are mainly used in the pharmacotherapy for HRS, and at present, terlipressin combined with albumin is the first-line treatment method for HRS. Some drugs with a renal vasodilatory effect also show a potential therapeutic effect. This article reviews the latest research advances in the role and clinical application of vasoactive drugs in the treatment of HRS.
